Global Head of Benefit-Risk Evaluation - Sanofi
Stephanie, public health physician, has over 17 years of experience working in pharma companies on Pharmacoepidemiology and BR evaluation to support market access, pricing and risk management plans. After her appointments at Eli Lilly, she joined Global Pharmacovigilance & Epidemiology department at Sanofi in 2010 as a Global Pharmacoepidemiologist, as a Pharmacoepidemiology Lead in 2016 and Head of Benefit-Risk evaluation in 2017. Stephanie is one of the leading experts in the qualitative and quantitative BR field and has conducted several benefit-risk analyses for development and marketed drugs for over 10 years.
Subscribe today to receive news on latest updates,
offers and upcoming conferences via email
Follow us online to stay up to date about our conferences